Browse DACT1

Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Cell junction, synapse Note=Shuttles between the nucleus and the cytoplasm. Seems to be nuclear in the absence of Wnt signaling and to translocate to the cytoplasm in its presence.
Domain PF15268 Dapper
Function

Involved in regulation of intracellular signaling pathways during development. Specifically thought to play a role in canonical and/or non-canonical Wnt signaling pathways through interaction with DSH (Dishevelled) family proteins. The activation/inhibition of Wnt signaling may depend on the phosphorylation status. Proposed to regulate the degradation of CTNNB1/beta-catenin, thereby modulating the transcriptional activation of target genes of the Wnt signaling pathway. Its function in stabilizing CTNNB1 may involve inhibition of GSK3B activity. Promotes the membrane localization of CTNNB1. The cytoplasmic form can induce DVL2 degradation via a lysosome-dependent mechanism; the function is inhibited by PKA-induced binding to 14-3-3 proteins, such as YWHAB. Seems to be involved in morphogenesis at the primitive streak by regulating VANGL2 and DVL2; the function seems to be independent of canonical Wnt signaling and rather involves the non-canonical Wnt/planar cell polarity (PCP) pathway (By similarity). The nuclear form may prevent the formation of LEF1:CTNNB1 complex and recruit HDAC1 to LEF1 at target gene promoters to repress transcription thus antagonizing Wnt signaling. May be involved in positive regulation of fat cell differentiation. During neuronal differentiation may be involved in excitatory synapse organization, and dendrite formation and establishment of spines.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001933 negative regulation of protein phosphorylation
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007164 establishment of tissue polarity
GO:0007254 JNK cascade
GO:0007346 regulation of mitotic cell cycle
GO:0007442 hindgut morphogenesis
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010948 negative regulation of cell cycle process
GO:0016055 Wnt signaling pathway
GO:0017038 protein import
GO:0021915 neural tube development
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031333 negative regulation of protein complex assembly
GO:0031647 regulation of protein stability
GO:0032091 negative regulation of protein binding
GO:0032092 positive regulation of protein binding
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032873 negative regulation of stress-activated MAPK cascade
GO:0033157 regulation of intracellular protein transport
GO:0034504 protein localization to nucleus
GO:0035239 tube morphogenesis
GO:0035411 catenin import into nucleus
GO:0035412 regulation of catenin import into nucleus
GO:0035413 positive regulation of catenin import into nucleus
GO:0035567 non-canonical Wnt signaling pathway
GO:0042176 regulation of protein catabolic process
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042326 negative regulation of phosphorylation
GO:0043254 regulation of protein complex assembly
GO:0043393 regulation of protein binding
GO:0043409 negative regulation of MAPK cascade
GO:0044744 protein targeting to nucleus
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045732 positive regulation of protein catabolic process
GO:0045786 negative regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0046328 regulation of JNK cascade
GO:0046329 negative regulation of JNK cascade
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048546 digestive tract morphogenesis
GO:0048565 digestive tract development
GO:0048619 embryonic hindgut morphogenesis
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051100 negative regulation of binding
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051403 stress-activated MAPK cascade
GO:0055123 digestive system development
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061525 hindgut development
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070303 negative regulation of stress-activated protein kinase signaling cascade
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090175 regulation of establishment of planar polarity
GO:0090316 positive regulation of intracellular protein transport
GO:0198738 cell-cell signaling by wnt
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902532 negative regulation of intracellular signal transduction
GO:1902593 single-organism nuclear import
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904837 beta-catenin-TCF complex assembly
GO:1904863 regulation of beta-catenin-TCF complex assembly
GO:1904864 negative regulation of beta-catenin-TCF complex assembly
GO:1904951 positive regulation of establishment of protein localization
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000050 regulation of non-canonical Wnt signaling pathway
GO:2000095 regulation of Wnt signaling pathway, planar cell polarity pathway
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0001085 RNA polymerase II transcription factor binding
GO:0005080 protein kinase C binding
GO:0008013 beta-catenin binding
GO:0008134 transcription factor binding
GO:0042826 histone deacetylase binding
GO:0051018 protein kinase A binding
GO:0070097 delta-catenin binding
Cellular Component GO:0030877 beta-catenin destruction complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-4641258: Degradation of DVL
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DACT1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DACT1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DACT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7820.0266
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5270.568
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9610.129
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.340.419
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.130.94
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6010.793
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0180.97
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6760.521
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.630.556
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5650.58
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0820.0925
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3650.0711
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DACT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DACT1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DACT1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DACT1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DACT1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DACT1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DACT1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDACT1
Namedishevelled-binding antagonist of beta-catenin 1
Aliases DAPPER1; THYEX3; HDPR1; DAPPER; FRODO; dapper homolog 1, antagonist of beta-catenin (xenopus); dapper, antag ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DACT1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.